Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
S. G. Danielli, Y. Wei, M. A. Dyer, E. Stewart, M. Wachtel, B. W. Schaefer, A. G. Patel, D. M. Langenau
This study identifies therapy-resistant and tumor-acquired cell states in pediatric rhabdomyosarcoma using single-cell RNA sequencing.
bioRxiv · Oct 13, 2023Cancer Biology
R. H. Chapple, X. Liu, S. Natarajan, M. I. M. Alexander, Y. Kim, A. G. Patel, C. W. LaFlamme, M. Pan, W. C. Wright, H.-M. Lee, Y. Zhang, M. Lu, S. C. Koo, C. Long, J. Harper, , P. Geeleher
The paper compares mesenchymal-like gene expression programs in neuroblastoma preclinical models and patient tumors using single-cell RNA-seq and identifies chemotherapy-induced changes in PDX and GEMM.
bioRxiv · Apr 13, 2023Cancer Biology
M. K. Graham, B. Xu, C. Davis, A. K. Meeker, C. M. Heaphy, S. Yegnasubramanian, M. A. Dyer, M. Zeineldin
This study shows that TERT promoter hypomethylation and chromatin state differ in neuroblastoma based on telomere maintenance mechanisms, with repressive marks in long telomere-associated cells.
bioRxiv · May 18, 2022Cancer Biology
A. G. Patel, X. Chen, X. Huang, M. R. Clay, N. Komarova, M. J. Krasin, A. Pappo, H. Tillman, B. A. Orr, J. McEvoy, B. Gordon, K. Blankenship, C. Reilly, X. Zhou, J. L. Norrie, , M. A. Dyer
This study shows that targeting developmental states in rhabdomyosarcoma can prevent disease recurrence by eliminating myoblast-like cells and inhibiting EGFR-dependent paraxial mesoderm populations.
bioRxiv · Jun 16, 2021Cancer Biology
M. Pan, C. Wright, R. Chapple, A. Zubair, M. Sandhu, J. Batchelder, J. Low, K. Blankenship, L. Wang, B. Gordon, P. Archer, S. W. Brady, S. Natarajan, M. Pozsgai, J. Schuetz, , P. Geeleher
This study identifies CX-5461 as a TOP2B inhibitor with selective activity in high-risk neuroblastoma but highlights safety concerns due to TOP2B off-target effects.
bioRxiv · Feb 25, 2021Cancer Biology